Comparative Pharmacology
Head-to-head clinical analysis: DYAZIDE versus METHYCLOTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYAZIDE versus METHYCLOTHIAZIDE.
DYAZIDE vs METHYCLOTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Thiazide-like diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reduces peripheral vascular resistance.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
2.5-10 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin."
Clinical Note
moderateMethyclothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside."
Clinical Note
moderateTriamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Terminal elimination half-life: ~40 hours (range 30-50 h); due to extensive tubular reabsorption, half-life is prolonged in renal impairment and elderly, allowing once-daily dosing
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Primarily renal (70-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal (<10%)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Methyclothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin."